Dagmar Rosa-Bjorkeson, a director of Intercept Pharmaceuticals, appears to have filed an empty initial statement of beneficial ownership. This form is usually filed as a prelude to a company officer either receiving options or buying company shares, so there may be more to come from Rosa-Bjorkeson.
Here is the filing.
To get notified when Intercept Pharmaceuticals makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022